Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Mari L DeMarco

Showing results (61-70 of 74) with videos related to

Pageof 8
Sort By:
Open Forum Infectious Diseases|March 13, 2023
Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA VaccineFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
Viruses|May 25, 2024
T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral TherapySneha Datwani, Rebecca Kalikawe, Rachel Waterworth, et al.
Cell|March 5, 2022
Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseasesAndrew Chang, Xinyu Xiang, Jing Wang, et al.
The Journal of Infectious Diseases|December 10, 2021
Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older AdultsMark A Brockman, Francis Mwimanzi, Hope R Lapointe, et al.
Frontiers in Immunology|September 23, 2022
Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccinationHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
The Journal of Infectious Diseases|May 11, 2022
Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third DoseFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|January 12, 2022
Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third DoseFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
AIDS (London, England)|December 22, 2022
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapyHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|October 21, 2021
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapyZabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2022
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Pageof 8

Showing results (61-70 of 74) with videos related to

Sort By:
Pageof 8
Open Forum Infectious Diseases|March 13, 2023
Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA VaccineFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
Viruses|May 25, 2024
T-Cell Responses to COVID-19 Vaccines and Breakthrough Infection in People Living with HIV Receiving Antiretroviral TherapySneha Datwani, Rebecca Kalikawe, Rachel Waterworth, et al.
Cell|March 5, 2022
Homotypic fibrillization of TMEM106B across diverse neurodegenerative diseasesAndrew Chang, Xinyu Xiang, Jing Wang, et al.
The Journal of Infectious Diseases|December 10, 2021
Reduced Magnitude and Durability of Humoral Immune Responses to COVID-19 mRNA Vaccines Among Older AdultsMark A Brockman, Francis Mwimanzi, Hope R Lapointe, et al.
Frontiers in Immunology|September 23, 2022
Serial infection with SARS-CoV-2 Omicron BA.1 and BA.2 following three-dose COVID-19 vaccinationHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
The Journal of Infectious Diseases|May 11, 2022
Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third DoseFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|January 12, 2022
Older Adults Mount Less Durable Humoral Responses to a Two-dose COVID-19 mRNA Vaccine Regimen, but Strong Initial Responses to a Third DoseFrancis Mwimanzi, Hope R Lapointe, Peter K Cheung, et al.
AIDS (London, England)|December 22, 2022
Antibody response durability following three-dose coronavirus disease 2019 vaccination in people with HIV receiving suppressive antiretroviral therapyHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Medrxiv : the Preprint Server for Health Sciences|October 21, 2021
Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapyZabrina L Brumme, Francis Mwimanzi, Hope R Lapointe, et al.
Medrxiv : the Preprint Server for Health Sciences|March 30, 2022
People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responsesHope R Lapointe, Francis Mwimanzi, Peter K Cheung, et al.
Pageof 8